| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 2 | +15.9K | 100% | $8.63 | +$137K |
| Sells | 0 | ||||
| Net | +2 | +15.9K | 100% | +$137K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | Director | $47.4M | May 5, 2025 | ||
| Steven Salamon | Director | $47.4M | May 15, 2025 | ||
| Gil Aharon | Director | $47.4M | May 15, 2025 | ||
| Gerard Michel | CHIEF EXECUTIVE OFFICER, Director | $2.82M | +$98K | +3.6% | Nov 11, 2025 |
| Vojo Vukovic | Chief Medical Officer | $807K | Jun 12, 2025 | ||
| David Hoffman | Gen'l Counsel, Cco & Secy | $277K | Feb 7, 2025 | ||
| Sandra Pennell | Chief Financial Officer | $227K | Feb 7, 2025 | ||
| John Richard Sylvester | Director | $133K | +$39K | +41.6% | Nov 21, 2025 |
| John Purpura | Chief Operating Officer | $125K | Feb 8, 2023 | ||
| Kevin Muir | Gm Interventional Oncology | $69.1K | Feb 7, 2025 | ||
| Christine Padula | Interim Principal Accounting Officer | Sep 1, 2021 | |||
| Bridget Martell | Director | May 15, 2025 | |||
| Roger G. Stoll Phd | Director | May 23, 2024 | |||
| Martha S. Rook | Chief Operating Officer | Feb 7, 2025 | |||
| Johnny John | Svp Clinical Dev & Med Affairs | Feb 8, 2023 | |||
| Elizabeth Czerepak | Director | May 15, 2025 | |||
| Anthony Dias | Vp Finance | Feb 8, 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|